Newly Approved Lebrikizumab Shows Promise in AD Patients With Darker Skin
Andrew F. Alexis, MD, MPH, Professor of Clinical Dermatology at Weill Cornell Medicine in New York, NY, discusses preliminary study results showing that the newly U.S. Food and Drug Administration-approved biologic, lebrikizumab-lbkz (Ebglyss, Lilly), improves post-inflammatory hyperpigmentationsecondary to atopic dermatitis in people with darker skin tones.